Evidence check: HbA1c in the context of weight loss

HbA1c (glycated hemoglobin) is a well-established biomarker reflecting average blood glucose over the preceding 2–3 months. In the context of weight loss, evidence shows that a significant reduction in body weight (≥5 %) in overweight or obese individuals improves insulin sensitivity and can lower HbA1c levels. Clinical trials such as the Diabetes Prevention Program (DPP) and the Look AHEAD study demonstrate that lifestyle interventions leading to weight loss reduce HbA1c in prediabetes and type 2 diabetes. However, HbA1c is not a direct measure of weight loss itself but of glycemic control. In metabolically healthy individuals without insulin resistance, moderate weight loss may have only a minor effect on HbA1c. The overall evidence is rated as human-moderate, based on numerous observational and interventional studies, though not all are randomized controlled. Caveats: HbA1c can be confounded by anemia, hemoglobin variants, or renal impairment. For individual assessment, fasting glucose and possibly an oral glucose tolerance test should be considered. MyBody-X blood tests measure HbA1c but do not replace medical diagnosis.